#Canada #Montreal #Thryv Therapeutics #SGK1 inhibitors #Long QT Syndrome

Thryv Therapeutics Participation in Piper Sandler Virtual Cardio Day

Thryv Therapeutics Inc., a Montreal-based biotechnology firm specializing in innovative cardiovascular disease therapies, has announced its participation in the upcoming 2025 Piper Sandler Virtual Cardio Day. Scheduled for April 1, 2025, this exclusive, invitation-only event will serve as a platform for the company's leadership to present its latest research breakthroughs.

Event Details

During the conference, Thryv Therapeutics will engage in a fireside chat from 11:30 AM to 11:55 AM ET. This session will feature discussions led by:

• - Paul Truex - Chairman and CEO
• - Dr. Amy Sehnert - Chief Medical Officer

Together, they will provide insights into their ongoing research and the novel therapies they are developing to tackle serious cardiovascular issues such as Long QT Syndrome, heart failure, and atrial fibrillation.

Focus on SGK1 Inhibitors

Central to Thryv's research is their pioneering work on serum glucocorticoid inducible kinase 1 (SGK1) inhibitors. These agents represent a promising new class of treatments that aim to revolutionize how specific cardiovascular diseases are managed. SGK1 inhibitors are designed to act selectively, offering hope for patients suffering from conditions that affect the heart's rhythm and overall functionality.

The leadership will outline the company's strategic approach to precision medicine, which aims to tailor treatments more effectively for individual patients. This is particularly important for serious conditions where existing therapies may not provide adequate relief.

Join the Discussion

Piper Sandler's Virtual Cardio Day is tailored for the firm’s clients, providing them with exclusive insights into emerging trends and innovations in cardiovascular health. This year's event promises to be especially engaging, as it will feature forward-thinking discussions on Thryv's research initiatives.

Interested parties can access the webcast through their Piper Sandler representative to tune into real-time insights and updates.

About Thryv Therapeutics

Thryv Therapeutics Inc. operates with a mission to advance the field of cardiology with groundbreaking therapies that can fundamentally change patient outcomes. Founded in Montreal, Quebec, Thryv focuses on a precise, methodical approach to biomedical research, ensuring the development of powerful and selective medications tailored for diverse heart conditions. With their innovative strategies, they are positioned to make a significant impact on the treatment of cardiovascular diseases.

For more detailed information on their initiatives and ongoing projects, visit Thryv Therapeutics official website.

Thryv Therapeutics is poised to continue its trajectory of significant growth and innovation within the biotech sector, working diligently towards a future where heart diseases are managed with advanced, effective therapies.